Effect of Intranasal Insulin on Cognitive Processes and Appetite

April 30, 2019 updated by: University of Birmingham

Interactions Between Metabolic, Cognitive and Reward Processes in Appetite - Effects of Intranasal Administration of Insulin

This study investigates the effect of intranasal insulin on cognitive processes (behavioural and neural) in healthy lean and obese female adults. All subjects will receive a single-dose of intranasal insulin and/or placebo (on different days) before participating in several cognitive tasks.

Study Overview

Status

Completed

Conditions

Detailed Description

It is well established that eating behaviour is affected by metabolic signals (e.g. insulin, ghrelin, serotonin) and is also modulated via food reward processes. However, in humans, eating behaviour is a complex process, which involves habits, long-term goals and social interaction. Thus, recently it has been proposed that higher cognitive processes such as inhibitory control, attention and memory also modulate eating.

Insulin seems to be involved in both metabolic processes and cognitive processes. In the last decade it has been shown that intranasal administration of insulin decreases food intake, especially in women, and enhances thermogenesis and memory. In addition intranasal insulin administration has been shown to affect brain areas related to homeostatic control, reward and memory.

In the proposed study the investigators will examine the effect of intranasal insulin administration on eating, and on metabolic, reward and cognitive processes and their potential interplay. The investigators will also study the effect of body weight on the actions of insulin on these processes.

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy female subjects
  • Age 18-65 years at start of the study
  • Body Mass Index (BMI) between 18 and 25 kg/m2 for the lean group and between 30 and 40 kg/m2 for the obese group
  • Right-handedness (including left-handers could bias the results because of the laterality of brain functions)
  • Ability to give informed consent
  • Fluent English speaking
  • Willingness to be informed about chance findings of pathology

Exclusion Criteria:

  • Subjects who have a non-removable metal object in or at their body, such as, for example: Heart pace-maker, artificial heart valve, metal prosthesis, implants or splinters, non-removable dental braces
  • Tattoos, that are older than 15 years
  • Claustrophobia
  • Limited temperature perception and/or increased sensitivity to warming of the body
  • Pathological hearing ability or an increased sensitivity to loud noises
  • Lack of ability to give informed consent
  • Operation less than three months ago
  • Simultaneous participation in other studies that involve drugs intake or blood spending
  • Acute illness or infection during the last 4 weeks
  • Cardiovascular disorders (e.g., hypertrophic cardiomyopathy, long QT syndrome)
  • Moderate or severe head injury
  • Eating disorders
  • No metabolic (e.g. metabolic disorder, diabetes, insulin resistance), psychological (e.g. depression) or neurological (e.g. epilepsy, headache disorder, multiple sclerosis, traumatic brain injuries) diseases or medication in relation to these diseases.
  • Intake of any medication that can interfere with the drug or measurements.
  • Current weight loss regimens, or more then 5kg weight loss in the last 3 months
  • Smoking
  • Current pregnancy or breastfeeding
  • Current or past history of drug or alcohol dependency - alcohol consumption exceeding 12 units a week
  • Food allergies (e.g. peanut allergy lactose and gluten intolerance) or vegetarian/vegan diet
  • Disliking the study lunch

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Insulin
In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
Intranasal insulin
Other Names:
  • Insulin
  • Actrapid
Placebo Comparator: Placebo
In this arm a single-dose intranasal placebo will be administrated
Intranasal placebo manufactured to mimic smell of insulin
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
fMRI brain response during inhibition to a food stimuli
Time Frame: 14 minutes
Neural activation during correct inhibition food vs. non-food stimuli trail. Comparing the brain response when subjects correctly withhold for food vs a sports item.
14 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delay discount of food reward
Time Frame: 5 minutes
Area under the curve for delay of choosing a food item. Subjects have to choice between a certain amount of food now, or more (which varies between 1-20 pieces) food later (which will vary from 1 hour to 1 year).
5 minutes
Delay discount of money reward
Time Frame: 5 minutes
Area under the curve for delay of choosing a amount of money. Subjects have to choice between a certain amount of money now, or more (which varies between 1-100 pound) money later (which will vary from 1 day, 1 months and 1 year).
5 minutes
fMRI brain activity in food picture task
Time Frame: 18 minutes
Brain responses for food stimuli compared to non-food stimuli. The researchers will measure this by showing subjects food and non-food images while preforming and fMRI-scan and subtract activity during non-food images from the activity pattern when looking at food images.
18 minutes
Recall pictures
Time Frame: 5 minutes
Recall accuracy. The researchers will count the correct amount of pictures remembered in this task and calculate % of pictures remembered in total, and differentiate between the three categories (high caloric/low caloric/control)
5 minutes
Recall words
Time Frame: 10 minutes
Recall words. The researcher will count the correct amount of words remembered in this task
10 minutes
Emotional categorisation
Time Frame: 10 minutes
Accuracy of category and reaction time will be measured for dislike or like words
10 minutes
Emotional recall part 1
Time Frame: 4 minutes
Recall words of liked and disliked words will be recorded in ECAT
4 minutes
Emotional recall part 1
Time Frame: 10 minutes
Accuracy of previous exposed or not exposed words will be measured
10 minutes
Cookie intake
Time Frame: 10 minutes
Amount (kcal and gram) of cookies eaten will be measured
10 minutes
fMRI neural network during inhibition to a food stimuli
Time Frame: 14 minutes
Functional connectivity during correct inhibition food vs. non-food stimuli trail.
14 minutes
fMRI brain responses during inhibition
Time Frame: 14 minutes
Neural activation correct No-Go vs. Go trail. Subjects neural activation when they are instructed to go (press) when seeing toiletry or stationary items and react correctly compared to when subjects are instructed not to go (no press) when seeing a food or sport and withhold correctly
14 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maartje SPetter, PhD, Univerisity of Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2018

Primary Completion (Actual)

April 1, 2019

Study Completion (Actual)

April 1, 2019

Study Registration Dates

First Submitted

August 13, 2018

First Submitted That Met QC Criteria

August 13, 2018

First Posted (Actual)

August 15, 2018

Study Record Updates

Last Update Posted (Actual)

May 2, 2019

Last Update Submitted That Met QC Criteria

April 30, 2019

Last Verified

August 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • RG_17-102

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The study protocol and data will be shared on Open Science Forum

IPD Sharing Time Frame

The study protocol will be shared before including the first participant. The data will become available after the last participant has finished the study.

IPD Sharing Access Criteria

All researchers

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Intranasal Insulin

3
Subscribe